27 reports

  • 10.3 ALLERGAN

Ophthalmology, ##(##), pp. ##-##. ##(##), PP. ##-##.

  • Ophthalmic Solution
  • Forecast
  • Allergan plc
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

The auto exports exceeded over ## million each year.

  • Diagnostic Reagent
  • China
  • Demand
  • Market Size
  • Biosino Bio-Technology & Science Inc

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group
  • Strengths
  • Vendor landscape

It blocks IL-## receptor signaling and prevents the binding of IL-## alpha and IL-## beta to the IL-## receptor.

  • Ophthalmic Solution
  • Ophthalmology
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc

Therefore, the consumer demand for digestive enzymes is increasing, as adequate digestive enzymes could improve gastrointestinal health and solve several other health issues caused or exacerbated by enzyme deficiency.

  • Ophthalmic Solution
  • Canada
  • Demand
  • Bayer AG
  • Jamieson Laboratories Ltd.

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

TEAR FILM MUCINS: FRONT LINE DEFENDERS OF THE OCULAR SURFACE; COMPARISON WITH AIRWAY AND GASTROINTESTINAL TRACT MUCINS.

  • Ophthalmic Solution
  • Market Size
  • Allergan plc
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Moreover, vitamins and dietary supplements must not be advertised for any specific medicinal purpose, such as cardiovascular or gastrointestinal disease.

  • Ophthalmic Solution
  • OTC
  • Singapore
  • Demand

Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins.

  • Ophthalmic Solution
  • Allergan plc
  • Mitotech S.A.
  • RegeneRx Biopharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders.

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • M&A
  • NicOx S.A.

-based multicenter, ##:## randomized, double-masked, vehicle-controlled trial is enrolling patients who exhibit chronic signs and symptoms of allergic conjunctivitis.

  • Ophthalmic Solution
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The company reported that it has demonstrated the activity of AK-## in preclinical studies including respiratory, dermatological, gastrointestinal, and allergic disease models.

  • Ophthalmic Solution
  • Therapy
  • United States
  • Product Initiative
  • Aldeyra Therapeutics, Inc.

The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated

The molecules developed by Companies in Phase III, Phase II and Preclinical stages are ##, ## and ## respectively.

  • Eye Disease
  • Ophthalmic Solution
  • United States
  • Litigation And Patent
  • InSite Vision Incorporated

s wholly owned subsidiary, Bausch + Lomb, announced that its unique ONE by ONE Recycling Program has recycled a combined total of more than one million used contact lenses, blister packs and top foils in less than one year since its launch.

  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Company
  • Bausch & Lomb Incorporated

s wholly owned subsidiary, Bausch + Lomb, announced that its unique ONE by ONE Recycling Program has recycled a combined total of more than one million used contact lenses, blister packs and top foils in less than one year since its launch.

  • Ophthalmic Solution
  • Ophthalmology
  • United States
  • Company
  • Bausch & Lomb Incorporated

Dermatology and Gastrointestinal businesses.

  • Ophthalmic Solution
  • Canada
  • North America
  • Company
  • Valeant Pharmaceuticals International, Inc.

Dermatology and Gastrointestinal businesses.

  • Ophthalmic Solution
  • Pharmaceutical
  • North America
  • Forecast
  • Valeant Pharmaceuticals International, Inc.

Dermatology and Gastrointestinal businesses.

  • Ophtalmic Surgery Device
  • Ophthalmic Solution
  • Canada
  • North America
  • Valeant Pharmaceuticals International, Inc.

Currently, the multiplexed Verigene tests target infections of the bloodstream, respiratory tract and gastrointestinal tract.

  • Healthcare
  • Ophthalmic Solution
  • North America
  • United States
  • Alcon, Inc.
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Allergy Drug
  • Eye Disease
  • Ophthalmic Solution
  • OTC
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Ophthalmic Solution
  • OTC
  • Pharmaceutical
  • World
  • Product Initiative

ITS MAJOR PRODUCT CATEGORIES INCLUDE ANALGESICS, COUGH/ COLD/ ALLERGY/ SINUS, GASTROINTESTINAL AND SMOKING CESSATION, AND SECONDARY PRODUCT CATEGORIES INCLUDE FEMININE HYGIENE, DIABETES CARE AND DERMATOLOGICAL CARE.

  • Ophthalmic Solution
  • United States
  • Company
  • M&A
  • Alcon, Inc.